文献速递淋巴瘤

套细胞淋巴瘤对PRMT5靶向治疗的耐药性

Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

套细胞淋巴瘤(MCL)患者对靶向治疗耐药后预后差。研究在患者来源异种移植(PDX)模型和细胞系中发现PRMT5抑制剂耐药表型可持久存在,耐药细胞与敏感细胞相比mTOR信号通路共同上调,用替西罗莫司靶向阻断mTORC1可克服耐药表型并改善耐药PDX生存。

要点

  • PRMT5抑制剂耐药的MCL细胞接种小鼠较未治疗细胞接种小鼠生存期缩短(P = .005)。
  • 敏感细胞系IC50为20-140 nM(n = 4),原发耐药为340-1650 nM(n = 4),诱导耐药为200-500 nM(n = 4)。
  • 耐药PDX和细胞系中mTOR信号通路共同上调,替西罗莫司可克服耐药并改善耐药PDX生存。

核心结论

  • MCL对PRMT5抑制剂可产生耐药,耐药表型在撤药后持续存在,且对PRT-808同样可见;耐药与mTOR信号通路上调相关,靶向阻断mTORC1可克服耐药表型并改善耐药PDX生存。

研究设计与样本

  • 研究使用患者来源异种移植(PDX)MCL模型和MCL细胞系,比较PRMT5抑制剂敏感与耐药细胞,并进行批量RNA测序和单细胞RNA测序分析。
  • 细胞系按PRT-382敏感性分类:敏感(n = 4;50%抑制浓度[IC50],20-140 nM)或原发耐药(n = 4;340-1650 nM)。
  • 敏感MCL细胞系经药物递增长期培养产生PRMT5抑制剂耐药细胞系(n = 4;200-500 nM)。

主要发现

  • 接种PRMT5抑制剂耐药细胞的小鼠较接种未治疗细胞的小鼠生存期缩短(P = .005)。
  • 耐药表型在无药物长期培养后持续存在,并可在PRT-808中观察到。
  • 在耐药PDX和细胞系模型中,在原始PRMT5抑制剂IC50浓度下即可实现对称二甲基精氨酸减少,提示替代耐药通路激活。
  • 耐药细胞系和PDX的批量RNA测序分别相对敏感细胞或短期处理细胞,突出显示包括雷帕霉素激酶机械靶点[mTOR]信号在内的多条通路共同上调(P < 10-5且z评分 > 0.3或 < 0.3)。
  • 单细胞RNA测序分析显示整体基因表达强烈偏移,耐药PDX MCL样本中mTOR信号上调。

临床怎么用

  • 作者通过实验显示,用替西罗莫司靶向阻断mTORC1可克服PRMT5抑制剂耐药表型,在耐药MCL细胞系中显示治疗协同作用,并改善耐药PDX的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma, and patients who relapse on targeted therapies have poor prognosis. Protein arginine methyltransferase 5 (PRMT5), an enzyme essential for B-cell transformation, drives multiple oncogenic pathways and is overexpressed in MCL. Despite the antitumor activity of PRMT5 inhibition (PRT-382/PRT-808), drug resistance was observed in a patient-derived xenograft (PDX) MCL model. Decreased survival of mice engrafted with these PRMT5 inhibitor-resistant cells vs treatment-naive cells was observed (P = .005). MCL cell lines showed variable sensitivity to PRMT5 inhibition. Using PRT-382, cell lines were classified as sensitive (n = 4; 50% inhibitory concentration [IC50], 20-140 nM) or primary resistant (n = 4; 340-1650 nM). Prolonged culture of sensitive MCL lines with drug escalation produced PRMT5 inhibitor-resistant cell lines (n = 4; 200-500 nM). This resistant phenotype persisted after prolonged culture in the absence of drug and was observed with PRT-808. In the resistant PDX and cell line models, symmetric dimethylarginine reduction was achieved at the original PRMT5 inhibitor IC50, suggesting activation of alternative resistance pathways. Bulk RNA sequencing of resistant cell lines and PDX relative to sensitive or short-term-treated cells, respectively, highlighted shared upregulation of multiple pathways including mechanistic target of rapamycin kinase [mTOR] signaling (P < 10-5 and z score > 0.3 or < 0.3). Single-cell RNA sequencing analysis demonstrated a strong shift in global gene expression, with upregulation of mTOR signaling in resistant PDX MCL samples. Targeted blockade of mTORC1 with temsirolimus overcame the PRMT5 inhibitor-resistant phenotype, displayed therapeutic synergy in resistant MCL cell lines, and improved survival of a resistant PDX.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Long ME, Koirala S, Sloan S, et al. Resistance to PRMT5-targeted therapy in mantle cell lymphoma. Blood Adv. 2024. PMID: 37782774. doi:10.1182/bloodadvances.2023010554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。